<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 2, 1998
REGISTRATION NO. 333-_________
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------------------------
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
---------------------------------------------
ADVANCE PARADIGM, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 75-2493381
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification Number)
545 EAST JOHN CARPENTER FREEWAY, SUITE 1570
IRVING, TEXAS 75062
(972) 830-6199
(Address, Including Zip Code,
and Telephone Number, Including
Area Code, of Registrant's Principal Executive Offices)
---------------------------------------------
DAVID D. HALBERT
CHAIRMAN OF THE BOARD, PRESIDENT AND CHIEF EXECUTIVE OFFICER
545 EAST JOHN CARPENTER FREEWAY, SUITE 1570
IRVING, TEXAS 75062
(972) 830-6199
(Name, Address, Including Zip Code,
and Telephone Number, Including Area Code,
of Agent for Service)
------------------------------------
With a copy to:
J. KENNETH MENGES, JR., P.C.
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
1700 PACIFIC AVENUE, SUITE 4100
DALLAS, TEXAS 75201
(214) 969-2800
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
From time to time after the effective date of this registration statement.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. [ X ]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
-------------------
If this form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.
[ ]
--------------------------------
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
TITLE OF SHARES TO BE REGISTERED PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
AMOUNT TO BE AGGREGATE PRICE PER AGGREGATE OFFERING REGISTRATION FEE
REGISTERED SHARE (1) PRICE(1)
===================================================================================================================================
<S> <C> <C> <C> <C>
Common Stock, par value $0.01 per share 876,078 shares $34 15/16 $30,607,975 $9,275
===================================================================================================================================
</TABLE>
(1) Estimated pursuant to rule 457(c) solely for the purpose of calculating the
amount of the registration fee based on the average of the high and low
prices of the Common Stock reported by the Nasdaq National Market on May
29, 1998.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE
SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL
BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING
PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.
===============================================================================
<PAGE> 2
Subject To Completion, Dated June 2, 1998
PROSPECTUS
876,078 SHARES
ADVANCE PARADIGM, INC.
Common Stock
------------------------
This Prospectus relates to an aggregate of 876,078 shares (the
"Shares") of common stock, par value $0.01 per share ("Common Stock"), of
Advance Paradigm, Inc. ("Advance" or the "Company"), a Delaware corporation,
which may be offered from time to time (the "Offering") by the persons listed
herein under "Selling Stockholders" (collectively, the "Selling Stockholders").
The Shares were acquired by the Selling Stockholders pursuant to the Company's
merger with Innovative Medical Research, Inc. ("IMR") (the "Transaction"). The
Common Stock issued to the Selling Stockholders in the Transaction was issued in
reliance on exemptions from the registration requirements of the Securities Act
of 1993, as amended (the "Securities Act"). In accordance with the terms of the
Transaction, the Company has agreed to register the Shares for resale by the
Selling Stockholders. The Shares are being registered under the Securities Act
on behalf of the Selling Stockholders to permit the public sale or other
distribution of the Shares.
The Shares may be sold or distributed from time to time by or for the
account of the Selling Stockholders in transactions on the Nasdaq National
Market ("Nasdaq"), in privately negotiated transactions (including sales
pursuant to pledges), in a combination of such methods or by any other legally
available means. Such methods of sale may be conducted by the Selling
Stockholders at market prices prevailing at the time of sale, at prices related
to such prevailing market prices or at prices otherwise negotiated. The Selling
Stockholders may effect such transactions directly, or indirectly through
broker-dealers or agents acting on their behalf and, in connection with such
sales, such broker-dealers or agents may receive compensation in the form of
commissions or discounts from the Selling Stockholders and/or the purchasers of
the Shares for whom they may act as agent or to whom they sell Shares as
principal or both (which commissions or discounts might be in excess of
customary commissions). See "Plan of Distribution."
The Company will not receive any of the proceeds from the sale of the
Shares offered hereby. The Company will bear all expenses incident to the
registration of the Shares under federal and state securities laws and the sale
of the Shares hereunder other than expenses incident to the delivery of the
Shares to be sold by the Selling Stockholders. Any transfer taxes payable on any
Shares and any commissions and discounts payable to underwriters, agents or
dealers will be paid by the Selling Stockholders.
The Common Stock is quoted on Nasdaq under the symbol "ADVP." On May
29, 1998, the last reported sale price for the Common Stock as reported by
Nasdaq was $35 7/16 per share. The Company had 8,904,472 shares of Common Stock
issued and outstanding as of March 31, 1998.
PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE MATTERS SET FORTH
UNDER THE CAPTION "RISK FACTORS" BEGINNING ON PAGE 5 OF THIS PROSPECTUS.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY
OF THIS PROSPECTUS. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus is June 2, 1998
INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NEITHER BE SOLD NOR MAY
OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES
EFFECTIVE. THIS PROSPECTUS SHALL NEITHER CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF ANY OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES
IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR
TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE.
<PAGE> 3
TABLE OF CONTENTS
<TABLE>
<CAPTION>
<S> <C>
Available Information....................................................................................2
Incorporation of Certain Documents by Reference..........................................................3
The Company..............................................................................................4
Risk Factors.............................................................................................5
Selling Stockholders....................................................................................10
Use of Proceeds.........................................................................................10
Plan of Distribution....................................................................................11
Legal Matters...........................................................................................11
Uncertainty of Forward Looking Statements...............................................................11
Experts.................................................................................................12
</TABLE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the
Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder (the "Exchange Act"), and, in accordance therewith, files
reports, proxy and information statements and other information with the
Securities and Exchange Commission (the "SEC"). The reports, proxy statements
and other information concerning the Company can be inspected and copied at the
public reference facilities maintained by the SEC at Judiciary Plaza, Room 1024,
450 Fifth Street, N.W., Washington, D.C. 20549, and at the SEC's regional
offices located at Citicorp Center, Suite 1400, 500 West Madison Street, Room
3190, Chicago, Illinois 60661 and at Seven World Trade Center, 13th Floor, New
York, New York 10048. Copies of such material can also be obtained from the SEC
at prescribed rates through the Public Reference Section of the SEC at 450 Fifth
Street, N.W., Washington, D.C. 20549. Such documents also may be obtained
through the website maintained by the SEC at http://www.sec.gov. Advance Common
Stock is listed on Nasdaq (ADVP). Such reports, proxy statements and other
information relating to the Company may also be inspected at the offices of
Nasdaq at 1735 K Street, N.W., Washington, D.C. 20006.
The Company has filed with the SEC a Registration Statement on Form S-3
under the Securities Act with respect to the Shares (such registration
statement, including all amendments and supplements thereto, is hereinafter
referred to as the "Registration Statement"). This Prospectus, which forms a
part of the Registration Statement, does not contain all of the information set
forth in the Registration Statement, certain parts of which have been omitted in
accordance with the rules and regulations of the SEC. Statements contained in
this Prospectus as to the contents of any contract, agreement or other document
are not necessarily complete and in each instance reference is made to the copy
of such contract, agreement or other document filed as an exhibit to the
Registration Statement or incorporated herein by reference, and each such
statement is deemed qualified in its entirety by such reference. The
Registration Statement and exhibits thereto may be inspected without charge at
the public reference facilities maintained by the SEC, regional offices of the
SEC and offices of the SEC and Nasdaq referred to above, and copies thereof may
be obtained from the SEC at prescribed rates.
No person has been authorized to give any information or to make any
representations other than those contained in or incorporated by reference in
this Prospectus in connection with the offer made by this Prospectus and, if
given or made, such information or representation must not be relied upon as
having been authorized by the Company or the Selling Stockholders. Neither the
delivery of this Prospectus nor any sale made hereunder shall under any
circumstances create an implication that there has been no change in the affairs
of the Company since the date hereof. This Prospectus does not constitute an
offer to sell or the solicitation of an offer to buy any security other than the
shares of Common Stock offered hereby, nor does it constitute an offer to sell
or a solicitation of an offer to buy any shares of
2
<PAGE> 4
Common Stock by anyone in any jurisdiction in which such offer or solicitation
is not authorized, or in which the person making such offer or solicitation is
not qualified to do so, or to any person to whom it is unlawful to make such
offer or solicitation.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents, filed by the Company (File No. 0-21447) with
the SEC pursuant to the Exchange Act, are incorporated herein by reference and
made a part of this Prospectus:
(i) the Company's Annual Report on Form 10-K for the fiscal year
ended March 31, 1997, as amended by the Form 10-K/A for the
fiscal year ended March 31, 1997;
(ii) the Company's Quarterly Report on Form 10-Q for the quarter
ended December 31, 1997;
(iii) the Company's Schedule 14A Proxy Statement dated July 29, 1997
relating to the 1997 Annual Meeting of Stockholders held
September 23, 1997;
(iv) the Company's Current Report on Form 8-K dated February 24,
1998.
Also incorporated by reference into this Prospectus are the following
documents filed by Advance with the SEC pursuant to the Securities Act:
(a) the description of the Company's Common Stock
contained in the Company's Registration Statement on
Form S-1 (No. 333-06931) filed with the SEC on June
26, 1996, as amended by Amendment No. 1 thereto filed
with the SEC on July 10, 1996, Amendment No. 2
thereto filed with the SEC on September 11, 1996,
Amendment No. 3 thereto filed with the SEC on
September 30, 1996, and Amendment No. 4 thereto filed
with the SEC on October 8, 1996.
All reports and other documents filed by the Company with the SEC
pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date
of the initial Registration Statement and prior to the termination of the
Offering shall be deemed incorporated by reference in this Prospectus and to be
a part hereof from the date of filing of such documents. Any statement contained
in this Prospectus or in a document incorporated or deemed to be incorporated by
reference in this Prospectus shall be deemed to be modified or superseded for
purposes of this Prospectus to the extent that a statement contained in this
Prospectus or in any other subsequently filed document that also is or is deemed
to be incorporated by reference herein modifies or supersedes such statement.
Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Prospectus.
The Company undertakes to provide without charge to each person to whom
a copy of this Prospectus has been delivered, upon the written or oral request
of such person, a copy of any or all of the documents incorporated by reference
herein, other than the exhibits to such documents, unless such exhibits are
specifically incorporated by reference into the information that this Prospectus
incorporates. Written or oral requests for such copies should be directed to
Advance Paradigm, Inc., 545 East John Carpenter Freeway, Suite 1570, Irving,
Texas 75062, Attention: Mr. Danny Phillips, telephone number (972) 830-6199.
3
<PAGE> 5
THE COMPANY
Advance is a leading independent provider of pharmacy benefit
management ("PBM") services to health benefit plan sponsors, based on the over
twelve million health plan members enrolled in the Company's programs. The
Company's primary focus is on the delivery of cost-effective, high quality,
integrated PBM services. In addition, the Company has developed and is expanding
its clinical expertise and disease management services to meet the specialized
needs of its plans' members, particularly those requiring costly, long-term and
recurring therapies. These services are designed to inform and educate health
benefit plan sponsors, their members and participating physicians of nationally
recognized practice guidelines for various disease states.
The Company's PBM services include clinical and benefit design
consultation, formulary and rebate administration, electronic point-of-sale
pharmacy claims processing, mail pharmacy distribution, pharmacy network
management, drug utilization review and data information reporting services. The
Company administers a pharmacy network that includes over 52,000 retail
pharmacies throughout the United States. In 1994, as a response to increasing
cost-containment pressures from payors, the Company began to utilize its
clinical and information systems capabilities to develop health benefit
management ("HBM") services. The Company's HBM services include disease
management, recommendation of clinical guidelines, patient and physician
profiling, case finding, compliance and outcome measurement, and patient
adequacy of care, quality of life and member satisfaction surveys.
The Company was incorporated in Delaware in July 1993 as a wholly owned
subsidiary of Advance Health Care ("AHC"). Immediately prior to the Company's
initial public offering in October 1996, AHC was merged with and into the
Company, with the Company being the surviving corporation. Currently, the
Company has four wholly owned subsidiaries, Advance Paradigm Mail Services, Inc.
("Advance Mail"), Advance Paradigm Data Services, Inc. ("Advance Data"), Advance
Paradigm Clinical Services, Inc. ("Advance Clinical") and IMR. Advance Mail was
incorporated in 1986 and began operations in early 1987 as a mail order
pharmacy. In 1992, Advance Data was incorporated to provide plan participants an
alternative for purchasing prescriptions through a network of retail pharmacies
and to provide claims adjudication services. In August 1993, AHC contributed all
of the capital stock of Advance Data and Advance Mail to the Company. In
December 1993, the Company acquired Advance Clinical, formerly a wholly owned
subsidiary of Blue Cross and Blue Shield of Maryland. In February 1998, the
Company merged with IMR, a privately held company.
The principal executive office of Advance is located at 545 East John
Carpenter Freeway, Suite 1570, Irving, Texas 75062, and its telephone number is
(972) 830-6199.
4
<PAGE> 6
RISK FACTORS
In addition to the other information set forth and incorporated by reference in
this Prospectus, prospective purchasers of the Shares should consider carefully
the following risk factors in evaluating an investment in the Company.
FLUCTUATIONS IN QUARTERLY OPERATING RESULTS; LENGTHY SALES CYCLE; FUTURE RESULTS
UNCERTAIN
The Company has experienced and may in the future experience
significant fluctuations in revenue and operating results from quarter to
quarter and from year to year due to a combination of factors, including: demand
for the Company's services; the size, timing of contract signings and
recognition of revenues from significant customer additions and losses;
increased competition; the Company's success in, and expense associated with,
developing and introducing new services; the availability of rebates from
pharmaceutical manufacturers; the length of the Company's sales cycles; the
Company's ability to increase staff to meet demand; economic conditions
generally or in specific industry segments; and other factors outside of the
control of the Company. As a result of all of these factors, there can be no
assurance that the Company will be profitable on a quarterly or annual basis.
Due to the foregoing, it is possible that the Company's operating results in
some future quarters will be below analysts' expectations, which in turn could
adversely affect the Company's stock price.
GROWTH OF HBM SERVICES
The Company is presently expending significant resources to develop and
expand its HBM services, and the Company anticipates that it will continue to
expend significant resources in the foreseeable future. The Company historically
has experienced expense increases when introducing new services. In addition,
the Company's strategy for expanding its HBM services entails the acquisition of
HBM services providers, or other transactions with such providers to acquire HBM
services capabilities. Because the HBM services market is in an emerging stage,
there can be no assurance that the Company will be able to consummate such
acquisitions or other transactions. Moreover, there can be no assurance that HBM
services developed or acquired by the Company will be profitable or that the
demand for such services will exist in the future. See "--Risk of Acquisitions."
MANAGEMENT OF GROWTH
The Company's business has grown rapidly in the last four years, with
total revenues increasing from $35.0 million in fiscal year 1994 to $476.7
million in fiscal year 1998. The Company's recent expansion has resulted in
substantial growth in the number of its employees (from 117 at March 31, 1994 to
655 at March 31, 1998), the scope of its operating and financial systems and the
geographic distribution of its operations and customers. This recent rapid
growth has placed, and if such growth continues will increasingly place, a
significant strain on the Company's management and operations. Accordingly, the
Company's future operating results will depend on the ability of its officers
and other key employees to continue implementing and improving its operations,
customer support and financial control systems, and to effectively expand, train
and manage its employee base. There can be no assurance that the Company will be
able to manage any future expansion successfully or provide the necessary
management resources to successfully manage its business, and any inability to
do so would have a material adverse effect on the Company's business, operating
results and financial condition.
DEPENDENCE ON CERTAIN KEY CUSTOMERS
The Company depends on a limited number of large customers for a
significant portion of its consolidated revenues. During fiscal year 1998, the
Company's two largest customers, United Mine Workers of America ("UMW") and the
State of Oklahoma, accounted for approximately 21% and 15%, respectively, of the
Company's consolidated revenues. During this period, the Company's five largest
customers accounted for approximately 57% of the Company's revenues. Loss of the
Company's accounts with UMW or the State of Oklahoma, or of any other customers
which account for a substantial portion of the Company's business, could have a
material adverse effect on the Company's business, operating results and
financial condition.
5
<PAGE> 7
POTENTIAL DECLINE IN REBATE REVENUE
Approximately 15% of the Company's consolidated revenues is
attributable to arrangements with drug manufacturers relating to volume-based
rebate payments as well as fees charged for other products and services. The
loss of the Company's account with any of the major drug manufacturers under
such arrangements or the failure of the Company to meet certain conditions under
such arrangements could have a material adverse effect upon the Company's
business, operating results and financial condition. Over the next few years as
patents expire covering many brand name drugs that currently have substantial
market share, generic products will be introduced that may substantially reduce
the market share of the brand name drugs. Historically, manufacturers of generic
drugs have not offered rebates on their drugs. In addition, the Company is
unable to predict the effect on rebate arrangements that might result if the
recent trend of consolidations and alliances in the drug and managed care
industry continues, particularly between pharmaceutical manufacturers and PBMs.
CONSOLIDATION AMONG CUSTOMERS
Over the past several years, insurance companies, HMOs and managed care
companies have experienced significant consolidation. The Company's managed care
customers have been and may continue to be subject to consolidation pressures.
Although the Company may benefit from certain consolidations in the industry,
there can be no assurance that additional customers will not be lost as a result
of acquisitions and no assurance that such activity will not have a material
adverse effect upon the Company's business, operating results and financial
condition. Consolidation, strategic alliances and in general continued intense
competition in the PBM industry have resulted in the past, and may result in the
future, in the loss of certain of the Company's customers. There can be no
assurance that new and renewal contracts will offset the revenues lost from
customers electing not to renew their contracts with the Company. The Company's
contracts with its customers typically provide for multi-year terms, with
automatic 12-month renewals thereafter unless terminated by either party to any
given contract upon written notice delivered prior to the annual renewal date.
See "--Dependence on Certain Key Customers."
COMPETITION
The PBM industry has become very competitive. The Company's competitors
include large, profitable and well established companies with substantially
greater financial, marketing and other resources than the Company. Several
competitors in the PBM business are owned by pharmaceutical manufacturers and
may possess purchasing and other advantages over the Company by virtue of such
ownership. Price competition in the PBM market has resulted in reduced margins
for many PBMs, including the Company. The Company believes that the primary
competitive factors include: independence from drug manufacturers and payors;
the quality, scope and costs of products and services offered to insurance
companies, HMOs, employers and other sponsors of health benefit plans ("plan
sponsors" or "customers") and plan participants; responsiveness to customers'
demands; the ability to negotiate favorable rebates and volume discounts from
drug manufacturers; the ability to identify and apply effective cost containment
programs utilizing clinical strategies; the ability to develop formularies; the
ability to market PBM and HBM services to health benefit plan sponsors; a strong
managed care customer base which supports the development of HBM products and
services; and the commitment to providing flexible, clinically oriented services
to customers. There can be no assurance that the Company will continue to remain
competitive with respect to the foregoing factors or successfully market
integrated PBM or HBM services to new customers. There can be no assurance that
consolidation and alliances within the PBM industry will not adversely impact
the operations and prospects for independent PBMs such as the Company.
RISK OF ACQUISITIONS
Part of the Company's strategy for growth includes acquisitions of
complementary services, technologies or businesses that could allow the Company
to offer a set of integrated services, in addition to PBM services, to better
serve the needs of health benefit plan sponsors. The Company completed the
merger with IMR in February 1998 and will continue to review future acquisition
opportunities. The Company's ability to expand successfully through acquisitions
depends on many factors, including the successful identification and acquisition
of services, technologies or businesses. In addition, acquisitions, once
consummated, involve many risks including difficulties in the assimilation of
the
6
<PAGE> 8
operations, services and products of the acquired company; the diversion of
management's attention from other business concerns; and the potential loss of
key employees of the acquired company. There is significant competition for
acquisition opportunities in the PBM and HBM industries. The Company may compete
for acquisition opportunities with other companies that have significantly
greater financial and management resources. There can be no assurance that the
Company will be successful in acquiring or integrating any such services,
technologies or businesses or once acquired, that the Company will be successful
in selling or integrating such services, technologies or businesses.
DEPENDENCE ON KEY MANAGEMENT
The Company believes that its continued success will depend to a
significant extent upon the continued services of its senior management, in
particular David D. Halbert, Chairman of the Board, Chief Executive Officer and
President of the Company. The loss of the services of Mr. David D. Halbert or
other persons in senior management could have a material adverse effect on the
Company's business.
INTANGIBLE ASSETS
At March 31, 1998, approximately $12.4 million, or 8% of the Company's
total assets consisted of intangible assets. These intangible assets are being
amortized over a period of 40 years. In the event of any sale or liquidation of
the Company, there can be no assurance that the value of such intangible assets
will be realized. In addition, any significant decrease in the value of such
intangible assets could have a material adverse effect on the Company's
business, operating results and financial condition.
GOVERNMENT REGULATION
The PBM industry is subject to extensive federal and state laws and
regulations, and compliance with such laws and regulations imposes significant
operational requirements for the Company. The regulatory requirements with which
the Company must comply in conducting its business vary from state to state.
Management believes that the Company is in substantial compliance with all
existing statutes and regulations material to the operation of its business. The
impact of future legislation and regulatory changes on the Company's business
cannot be predicted, and there can be no assurance that the Company will be able
to obtain or maintain the regulatory approvals required to operate its business.
From time to time, retail pharmacists have expressed opposition to mail order
pharmacies. Retail pharmacies, state pharmacy associations or state board of
pharmacies in some states have attempted to secure the enactment or promulgation
of statutes or regulations that could have the effect of hindering or in some
cases prohibiting the delivery of prescription drugs into such state by a mail
service pharmacy. In January 1998, the U.S. Food and Drug Administration ("FDA")
issued a Notice and Draft Guidance regarding the regulation of certain
activities of PBMs that are directly or indirectly controlled by drug
manufacturers. On April 6, 1998, the Company submitted written comments to the
FDA wherein the Company stated its position that the proposed regulations should
not apply to PBMs which are not owned by drug manufacturers. There can be no
assurance that such legislation or regulation, if subsequently adopted, would
not have a material adverse effect on the Company's business, operating results
and financial condition.
DEVELOPMENTS IN THE HEALTH CARE INDUSTRY
The health care industry is subject to changing political, economic and
regulatory influences that may affect the procurement practices and operation of
health care organizations. The Company's services are designed to function
within the structure of the health care financing and reimbursement system
currently being used in the United States. The Company believes that the
commercial value and appeal of its services may be adversely affected if the
current health care financing and reimbursement system were to be materially
changed. During the past several years, the United States health care industry
has been subject to an increase in governmental regulation of, among other
things, reimbursement rates. Certain proposals to reform the United States
health care system are currently under consideration by Congress. These
proposals may increase governmental involvement in health care and pharmacy
benefit management services and otherwise change the operating environment for
the Company's customers. Health care organizations may react to these proposals
and the uncertainty surrounding such proposals by curtailing or deferring
investments in cost containment tools and related technology such as the
Company's services. The Company cannot
7
<PAGE> 9
predict what effect, if any, such factors might have on its business, operating
results and financial condition. In addition, many health care providers are
consolidating which may result in greater bargaining power and lead to price
erosion of the Company's services. The failure of the Company to maintain
adequate price levels would have a material adverse effect on the Company's
business, operating results and financial condition. Other legislative or
market-driven reforms could have unpredictable effects on the Company's
business, operating results and financial condition.
POTENTIAL LIABILITY AND INSURANCE
Various aspects of the Company's business, including the dispensing of
pharmaceutical products and performance of clinical trials and HBM services, may
subject it to litigation and liability for damages. Clinical research services
involve a risk of liability for personal injury or death due to, among other
reasons, possible unforeseen adverse side effects or improper administration of
a new drug. Although the Company believes that its risk is reduced by
contractual indemnification provisions and insurance maintained by the Company
and the trial sponsors, the Company could be materially and adversely affected
if it were required to pay damages or incur defense costs in connection with a
claim that is outside the scope of its indemnity or insurance coverage, or if
the indemnity, although applicable, is not performed in accordance with its
terms. While the Company maintains and intends to maintain professional and
general liability insurance coverage, there can be no assurance that the Company
will be able to maintain such insurance in the future or that such insurance
will be available on acceptable terms or will be adequate to cover any or all
potential product or professional liability claims. A successful product or
professional liability claim in excess of the Company's insurance coverage could
have a material adverse effect upon the Company's business, operating results
and financial condition.
RISKS ASSOCIATED WITH CLINICAL TRIALS BUSINESS
In February 1998, the Company completed the merger with IMR, a clinical trials
and outcomes research business. IMR has derived, and may in the future derive a
significant portion of its net revenue from a relatively limited number of major
projects or customers. Most of IMR's contracts are terminable upon 60 to 90 days
notice by the trial/survey sponsor. The loss, delay or termination of any major
project or customer could have a material adverse effect on this business. In
addition, the clinical trials operations could be materially and adversely
affected by a general economic decline in the pharmaceutical or biotechnology
industries or by a reduction in the outsourcing of clinical trials expenditures.
The clinical trials business is dependent upon the extensive governmental
regulation of the drug development process, and the failure of IMR to comply
with applicable regulations could result in the termination of ongoing clinical
research or the disqualification of data for submission to regulatory
authorities, either of which could have a material adverse effect on the
clinical trials business. The business of IMR is dependent upon its founding
executive officers, Richard B. Lipton, M.D. and Walter Stewart, Ph.D., M.P.H.,
the loss of whom could have a material adverse effect on IMR.
TAX RISKS ASSOCIATED WITH 1996 MERGER
Immediately prior to the Company's initial public offering in October
1996, AHC was merged (the "Merger") with and into the Company. Although the
Merger was structured as a tax free event, if the Company were to be audited,
there can be no assurance that the Internal Revenue Service would not
successfully challenge the tax free treatment, which could have a material
adverse effect upon the Company's business, operating results and financial
condition.
CONTROL BY EXISTING STOCKHOLDERS
Executive officers and directors of the Company and their affiliates
own beneficially approximately 27% of the Company's outstanding Common Stock. As
a result, these stockholders may have the ability to control the Company and
influence its affairs and the conduct of its business. Such concentration of
ownership may have the effect of delaying, deferring or preventing a change in
control of the Company.
8
<PAGE> 10
VOLATILITY OF MARKET PRICE
The quoted price of the Common Stock could fluctuate widely in response
to variations in the Company's quarterly operating results, changes in earnings
estimates by securities analysts, changes in the Company's business and changes
in general market or economic conditions. In addition, in recent years, the
stock market has experienced extreme price and volume fluctuations which have
significantly affected the quoted prices of the securities of many growth
companies without regard to their specific operating performance. Such market
fluctuations could have a material adverse effect on the quoted price of the
Common Stock.
POSSIBLE ADVERSE EFFECT IN MARKET PRICE OF FUTURE SALES OF THE COMMON STOCK
Future sales of Common Stock, or the perception that such sales could
occur, could adversely affect the market price of the Company's Common Stock.
There can be no assurance as to when, and how may of, the Shares will be sold
and the effect such sales may have on the market price of the Company's Common
Stock. As of the date of this Prospectus, the Company has registered under the
Securities Act an aggregate of 5,381,931 shares (including 2,337,750 shares
issued or available for issuance under the Company's stock option plans) of the
Company's Common Stock for resale by certain selling stockholders from time to
time. In addition, 4,938,195 shares of the Company's Common Stock, which
includes shares issuable upon the exercise of certain convertible securities,
may be sold to the public, subject to certain statutory and contractual resale
restrictions. In the event of the issuance and subsequent resale of a
substantial number of shares of the Company's Common Stock, or a perception that
such sales could occur, there could be a material adverse effect on the
prevailing market price of the Company's Common Stock.
NO DIVIDENDS
The Company has never paid cash dividends on its Common Stock, and the
Company's Board of Directors does not anticipate paying cash dividends in the
foreseeable future. The Company currently intends to retain future earnings to
finance the ongoing operations and growth of the business. The payment of
dividends in the future will depend upon business decisions that will be made by
the Board of Directors of the Company from time to time based upon the results
of operations and financial condition of the Company and its subsidiaries and
such other considerations as the Board of Directors considers relevant.
9
<PAGE> 11
SELLING STOCKHOLDERS
The following table sets forth the name of each Selling Stockholder,
the number of shares of Common Stock beneficially owned by each Selling
Stockholder as of March 31, 1998, and the number of Shares registered hereby
that each Selling Stockholder may offer and sell pursuant to this Prospectus.
However, because the Selling Stockholders may offer all or a portion of the
Shares at any time and from time to time after the date hereof, the exact number
of Shares that each Selling Stockholder may retain upon completion of the
Offering cannot be determined at this time. To the knowledge of the Company,
none of the Selling Stockholders has had any material relationship with the
Company except as more fully described elsewhere in this Prospectus (including
the information incorporated by reference in this Prospectus).
<TABLE>
<CAPTION>
BENEFICIAL
OWNERSHIP
AFTER OFFERING
(ASSUMING ALL
BENEFICIAL OWNERSHIP SHARES REGISTERED
PRIOR TO OFFERING ARE SOLD)
----------------------- NUMBER OF SHARES --------------------
PERCENT BEING REGISTERED IN PERCENT
NAME SHARES OF TOTAL THE OFFERING SHARES OF TOTAL
<S> <C> <C> <C> <C> <C>
Walter Stewart 262,968 3.0 262,968 -- --
Richard Lipton 229,016 2.6 229,016 -- --
Stuart Bell 212,040 2.4 212,040 -- --
Joshua Liberman 42,681 * 42,681 -- --
Surya Hejeebu 17,210 * 17,210 -- --
Robert Cox 26,251 * 26,251 -- --
Curren Bell Trust 16,976 * 16,976 -- --
Kylie Bell Trust 16,976 * 16,976 -- --
Ian Bell Trust 16,976 * 16,976 -- --
Justin Lipton Trust 16,976 * 16,976 -- --
Lianna Lipton Trust 16,976 * 16,976 -- --
Robert Sandler 1,032 * 1,032 -- --
</TABLE>
- ---------
*Less than 1%.
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale of the
Shares offered hereby. The Company will bear all expenses incident to the
registration of the Shares under federal and state securities laws and the sale
of the Shares hereunder other than expenses incident to the delivery of the
Shares to be sold by Selling Stockholders. Any transfer taxes payable on any
Shares and any commissions and discounts payable to underwriters, agents or
dealers will be paid by the Selling Stockholders.
10
<PAGE> 12
PLAN OF DISTRIBUTION
The Shares may be sold or distributed from time to time by or for the
account of the Selling Stockholders in transactions on Nasdaq, in privately
negotiated transactions (including sales pursuant to pledges), in a combination
of such methods, or by any other legally available means. Such methods of sale
may be conducted by the Selling Stockholders at market prices prevailing at the
time of sale, at prices related to such prevailing market prices or at prices
otherwise negotiated. The Selling Stockholders may effect such transactions
directly, or indirectly through broker-dealers or agents acting on their behalf
and, in connection with such sales, such broker-dealers or agents may receive
compensation in the form of commissions or discounts from the Selling
Stockholders and/or the purchasers of the Shares for whom they may act as agent
or to whom they sell Shares as principal or both.
The Shares may be sold from time to time by the Selling Stockholders,
or by pledgees, donees, transferees or other successors in interest. The Selling
Stockholders may also loan or pledge the Shares registered hereunder to a
broker-dealer and the broker-dealer may sell the Shares so loaned or upon a
default the broker-dealer may effect sales of the pledged Shares pursuant to
this Prospectus.
The Selling Stockholders and any such underwriters, brokers, dealers or
agents that participate in such distribution may be deemed to be "underwriters"
within the meaning of the Securities Act, and any discounts, commissions or
concessions received by any such underwriters, brokers, dealers or agents might
be deemed to be underwriting discounts and commissions under the Securities Act.
Neither the Company nor the Selling Stockholders can presently estimate the
amount of such compensation. The Company knows of no existing arrangements
between any Selling Stockholder and any other Selling Stockholder, underwriter,
broker, dealer or other agent relating to the sale or distribution of the
Shares.
Under applicable rules and regulations under the Exchange Act, any
person engaged in a distribution of any of the Shares may not simultaneously
engage in market activities with respect to the Common Stock except in
accordance with applicable law. In addition and without limiting the foregoing,
the Selling Stockholders will be subject to applicable provisions of the
Exchange Act; including without limitation Rule 10b-5 and Regulation M, which
provisions may limit the timing of purchases and sales of any of the Shares by
the Selling Stockholders. All of the foregoing may affect the marketability of
the Common Stock.
The Company has agreed to maintain the effectiveness of this
Registration Statement until the earlier of February 9, 2000 or the sale of all
of the Shares pursuant to this Prospectus. The Company will not receive any of
the proceeds from the sale of the Shares offered hereby. The Company will bear
all expenses incident to the registration of the Shares under federal and state
securities laws and the sale of the Shares hereunder other than expenses
incident to the delivery of the Shares to be sold by the Selling Stockholders.
Any transfer taxes payable on any Shares and any commissions and discounts
payable to underwriters, agents or dealers shall be paid by the Selling
Stockholders.
In order to comply with certain states' securities laws, if applicable,
the Shares will be sold in such jurisdictions only through registered or
licensed brokers or dealers. In addition, in certain states the Common Stock may
not be sold unless the Common Stock has been registered or qualified for sale in
such state or an exemption from registration or qualification is available and
is complied with.
LEGAL MATTERS
The validity of the Shares offered hereby has been passed upon for the
Company by Akin, Gump, Strauss, Hauer & Feld, L.L.P.
UNCERTAINTY OF FORWARD LOOKING STATEMENTS
This Prospectus includes "forward-looking statements" within the
meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than
statements of historical fact included in this Prospectus, including without
limitation, statements regarding the Company's financial position, the Company's
business strategy and the plans and objectives of management of the
11
<PAGE> 13
Company for future operations, are forward-looking statements. Although the
Company believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such expectations will
prove to have been correct. Important factors that could cause actual results to
differ materially from the Company's expectations are disclosed under "Risk
Factors", as well as elsewhere in this Prospectus. All subsequent written and
oral forward-looking statements attributable to the Company or persons acting on
behalf are expressly qualified in their entirety by this section.
EXPERTS
The financial statements and schedules of Advance Paradigm, Inc. as of
March 31, 1998, 1997 and 1996 and for each of the years in the three-year period
ended March 31, 1998, have been incorporated by reference herein and in the
registration statement in reliance upon the report of Arthur Andersen LLP,
independent certified public accountants, incorporated by reference herein, and
upon the authority of said firm as experts in accounting and auditing.
12
<PAGE> 14
INDEX TO FINANCIAL STATEMENTS
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
<TABLE>
<CAPTION>
<S> <C>
Report of Independent Public Accountants....................................................................F-2
Consolidated Balance Sheets--March 31, 1997 and 1998........................................................F-3
Consolidated Statements of Operations for the Years Ended March 31, 1996,
1997 and 1998............................................................................................F-4
Consolidated Statements of Stockholders' Equity for the Years Ended
March 31, 1996, 1997 and 1998............................................................................F-5
Consolidated Statements of Cash Flows for the Years Ended March 31, 1996,
1997 and 1998............................................................................................F-6
Notes to Consolidated Financial Statements..................................................................F-7
</TABLE>
F-1
<PAGE> 15
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Board of Directors and Stockholders of
Advance Paradigm, Inc.:
We have audited the accompanying consolidated balance sheets of Advance
Paradigm, Inc. (a Delaware corporation) and subsidiaries as of March 31, 1997
and 1998, and the related consolidated statements of operations, stockholders'
equity and cash flows for each of the three years in the period ended March 31,
1998. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Advance Paradigm, Inc. and
subsidiaries as of March 31, 1997 and 1998, and the results of their operations
and their cash flows for each of the three years in the period ended March 31,
1998, in conformity with generally accepted accounting principles.
ARTHUR ANDERSEN LLP
Dallas, Texas,
May 15, 1998
F-2
<PAGE> 16
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
ASSETS
<TABLE>
<CAPTION>
March 31,
------------------------------
1997 1998
------------- -------------
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 51,172,000 $ 58,342,000
Accounts receivable, net of allowance for doubtful accounts of
$192,000 and $247,000, respectively 36,269,000 68,335,000
Inventories 1,859,000 2,887,000
Prepaid expenses and other 427,000 1,487,000
------------- -------------
Total current assets 89,727,000 131,051,000
PROPERTY AND EQUIPMENT, net of accumulated depreciation
and amortization of $3,540,000 and $5,574,000, respectively 6,001,000 10,494,000
INTANGIBLE ASSETS, net of accumulated amortization of
$1,154,000 and $1,501,000, respectively 12,699,000 12,353,000
OTHER ASSETS 487,000 1,011,000
------------- -------------
Total assets $ 108,914,000 $ 154,909,000
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 59,857,000 $ 97,495,000
Accrued salaries and benefits 1,991,000 2,966,000
Income taxes payable 712,000 32,000
Other accrued expenses 1,692,000 2,196,000
Debt to related parties 900,000 --
------------- -------------
Total current liabilities 65,152,000 102,689,000
NONCURRENT LIABILITIES:
Deferred income taxes 844,000 1,285,000
Other noncurrent liabilities, less current portion 341,000 371,000
------------- -------------
Total liabilities 66,337,000 104,345,000
------------- -------------
COMMITMENTS AND CONTINGENCIES
PREFERRED STOCK:
Preferred stock, $.01 par value,
4,995,000 shares authorized, none issued and outstanding -- --
------------- -------------
STOCKHOLDERS' EQUITY:
Series B convertible preferred stock, $.01 par value; 5,000
shares authorized, 4,444 shares issued and outstanding -- --
Common stock, $.01 par value; 25,000,000 shares authorized,
8,676,895 and 8,904,472 shares issued and outstanding at
March 31, 1997 and 1998, respectively 87,000 89,000
Additional paid-in capital 42,888,000 43,142,000
Accumulated earnings (deficit) (398,000) 7,333,000
------------- -------------
Total stockholders' equity 42,577,000 50,564,000
------------- -------------
Total liabilities and stockholders' equity $ 108,914,000 $ 154,909,000
============= =============
</TABLE>
The accompanying notes are an integral part of these
consolidated financial statements.
F-3
<PAGE> 17
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Year Ended March 31,
-----------------------------------------------
1996 1997 1998
------------- ------------- -------------
<S> <C> <C> <C>
REVENUES $ 127,871,000 $ 256,450,000 $ 476,664,000
------------- ------------- -------------
COST OF OPERATIONS:
Cost of revenues 120,334,000 245,466,000 455,847,000
Selling, general and
administrative expenses 6,158,000 7,309,000 10,083,000
------------- ------------- -------------
Total cost of operations 126,492,000 252,775,000 465,930,000
------------- ------------- -------------
Operating income 1,379,000 3,675,000 10,734,000
INTEREST INCOME 366,000 1,560,000 2,814,000
INTEREST EXPENSE (732,000) (445,000) (67,000)
MERGER COSTS -- -- (689,000)
------------- ------------- -------------
INCOME BEFORE INCOME TAXES 1,013,000 4,790,000 12,792,000
PROVISION FOR INCOME TAXES -- 1,564,000 4,861,000
------------- ------------- -------------
NET INCOME $ 1,013,000 $ 3,226,000 $ 7,931,000
============= ============= =============
BASIC:
NET INCOME AVAILABLE
TO COMMON STOCKHOLDERS $ 213,000 $ 2,673,000 $ 7,731,000
NET INCOME PER SHARE $ 0.05 $ 0.43 $ 0.88
WEIGHTED AVERAGE SHARES OUTSTANDING 4,006,578 6,264,521 8,755,754
DILUTED:
NET INCOME AVAILABLE
TO COMMON STOCKHOLDERS $ 213,000 $ 3,226,000 $ 7,931,000
NET INCOME PER SHARE $ 0.05 $ 0.35 $ 0.70
WEIGHTED AVERAGE SHARES OUTSTANDING 4,576,265 9,176,127 11,350,919
</TABLE>
The accompanying notes are an integral part of these
consolidated financial statements.
F-4
<PAGE> 18
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED MARCH 31, 1996, 1997 AND 1998
<TABLE>
<CAPTION>
Series B Preferred
Common Stock Stock
------------------------ ----------------------- Additional Accumulated
Number of Number of Paid-In Earnings
Shares Amount Shares Amount Capital (Deficit) Total
---------- ---------- ---------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE, March 31, 1995........... 4,001,078 $ 40,000 -- $ -- $1,467,000 $(3,254,000) $(1,747,000)
Net income..................... -- -- -- -- -- 1,013,000 1,013,000
Dividends and accretion on
Series A Preferred Stock..... -- -- -- -- -- (820,000) (820,000)
Issuance of Common Stock
in connection with the
exercise of employee
stock options................ 5,500 -- -- -- 17,000 -- 17,000
---------- ---------- ---------- ---------- ---------- ---------- ----------
BALANCE, March 31, 1996........... 4,006,578 40,000 -- -- 1,484,000 (3,061,000) (1,537,000)
Net income..................... -- -- -- -- -- 3,226,000 3,226,000
Issuance of Common Stock
in connection with the
exercise of employee
stock options................ 3,000 -- -- -- 12,000 -- 12,000
Issuance of Series B
Preferred Stock.............. -- -- 4,444 -- 10,000,000 -- 10,000,000
Dividends and accretion on
Series A Preferred Stock..... -- -- -- -- -- (410,000) (410,000)
Issuance of Common Stock
in connection with an initial
public offering.............. 2,397,067 24,000 -- -- 19,111,000 -- 19,135,000
Issuance of Common Stock
in connection with the
conversion of Series A
Preferred Stock.............. 2,500,000 25,000 -- -- 12,279,000 -- 12,304,000
Reduction of Common Stock
outstanding in connection
with the merger with AHC..... (229,750) (2,000) -- -- 2,000 -- --
Dividends on Series B
Preferred Stock.............. -- -- -- -- -- (153,000) (153,000)
---------- ---------- ---------- ---------- ---------- ---------- ----------
BALANCE, March 31, 1997........... 8,676,895 87,000 4,444 -- 42,888,000 (398,000) 42,577,000
Net Income..................... -- -- -- -- -- 7,931,000 7,931,000
Issuance of Common Stock
in connection with the
exercise of stock options
and warrants................. 227,577 2,000 -- -- 254,000 -- 256,000
Dividends on Series B
Preferred Stock.............. (200,000) (200,000)
---------- ---------- ---------- ---------- ---------- ---------- ----------
BALANCE, March 31,1998............ 8,904,472 $ 89,000 4,444 $ -- $43,142,000 $7,333,000 $50,564,000
========== ========== ========== ========== ========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
F-5
<PAGE> 19
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Year Ended March 31,
--------------------------------------------
1996 1997 1998
------------ ------------ ------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 1,013,000 $ 3,226,000 $ 7,931,000
Adjustments to reconcile net income to net
cash provided by operating activities--
Depreciation and amortization 1,313,000 1,705,000 2,378,000
Provision for doubtful accounts 23,000 12,000 74,000
Change in certain assets and liabilities--
Accounts receivable (7,543,000) (12,612,000) (32,139,000)
Inventories (367,000) (261,000) (1,028,000)
Prepaid expenses and other assets (70,000) (256,000) (1,584,000)
Accounts payable, accrued expenses
and other noncurrent liabilities 20,985,000 23,571,000 38,907,000
------------ ------------ ------------
Net cash provided by operating activities 15,354,000 15,385,000 14,539,000
------------ ------------ ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (1,762,000) (3,147,000) (6,525,000)
------------ ------------ ------------
Net cash used in investing activities (1,762,000) (3,147,000) (6,525,000)
------------ ------------ ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of preferred stock -- 10,000,000 --
Net proceeds from issuance of Common Stock 17,000 19,147,000 256,000
Proceeds from borrowings 600,000 1,000,000 708,000
Payments on long-term obligations (244,000) (7,650,000) (1,608,000)
Payment of preferred stock dividend -- (153,000) (200,000)
------------ ------------ ------------
Net cash provided by (used in) financing
activities 373,000 22,344,000 (844,000)
------------ ------------ ------------
NET INCREASE IN CASH AND CASH EQUIVALENTS 13,965,000 34,582,000 7,170,000
CASH AND CASH EQUIVALENTS, beginning of year 2,625,000 16,590,000 51,172,000
------------ ------------ ------------
CASH AND CASH EQUIVALENTS, end of year $ 16,590,000 $ 51,172,000 $ 58,342,000
============ ============ ============
</TABLE>
SUPPLEMENTARY INFORMATION:
Cash paid for interest totaled approximately $732,000, $445,000 and $67,000
in 1996, 1997 and 1998, respectively.
The Company made income tax payments of $0, $19,000 and $5,100,000 in 1996,
1997 and 1998, respectively.
The accompanying notes are an integral part of these consolidated
financial statements.
F-6
<PAGE> 20
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. GENERAL:
Advance Paradigm, Inc. ("API"), a Delaware corporation formerly named
Advance Pharmacy Services, Inc., was formed as a wholly owned subsidiary of
Advance Health Care, Inc. ("AHC") in July 1993. The accompanying consolidated
financial statements include the accounts of API and its four wholly owned
subsidiaries, Advance Paradigm Mail Services, Inc. ("Advance Mail"), Advance
Paradigm Data Services, Inc. ("Advance Data"), Advance Paradigm Clinical
Services, Inc. ("Advance Clinical"), and Innovative Medical Research, Inc.
("IMR"), which collectively are referred to as "the Company".
The Company offers an integrated program of pharmacy benefit management.
Clinical, rebate and formulary products are provided through Advance Clinical.
Claims processing for prescription drugs purchased at the Company's network of
retail pharmacies is provided through Advance Data. The dispensing of
prescription drugs through the mail is provided through Advance Mail. The
Company markets health benefit management services ("HBM Services") to certain
health plans, pharmaceutical manufacturers, and other research and managed care
organizations, and programs for disease management services with selected
customers. In February 1998, API merged with IMR, a privately held clinical
trial and survey research firm.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Consolidation
The accompanying consolidated financial statements include the accounts of
API and its wholly owned subsidiaries. All significant intercompany accounts and
transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents include overnight investments, money market
accounts and high-grade commercial paper with original maturities of three
months or less.
F-7
<PAGE> 21
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
Inventories
Inventories consist of purchased pharmaceuticals stated at the lower of
cost or market under the first-in, first-out method.
Property and Equipment
Property and equipment are stated at cost less accumulated depreciation and
amortization. Depreciation is computed on the straight-line method over
estimated useful lives ranging from three to twenty years. Amortization of
leasehold improvements is computed over the lives of the assets or the lease
terms, whichever is shorter. Major renewals and betterments are added to the
property and equipment accounts while costs of repairs and maintenance are
charged to operating expenses in the period incurred. The cost of assets
retired, sold or otherwise disposed of and the applicable accumulated
depreciation are removed from the accounts, and the resultant gain or loss, if
any, is reflected in the statement of operations.
Intangible Assets
Intangible assets represent the excess of cost over the fair value of
tangible net assets acquired (goodwill) in connection with the acquisition of
Advance Clinical. Goodwill is amortized on a straight-line basis over 40 years.
Amortization expense was $346,000 in each of the years ended March 31, 1996,
1997 and 1998.
Impairment of Long-Lived Assets
The Company evaluates whether events and circumstances have occurred that
indicate the remaining estimated useful life of long-lived assets, including
goodwill, may warrant revision or that the remaining balance of an asset may not
be recoverable. The assessment of possible impairment is based on the ability to
recover the carrying amount of the asset from expected future cash flows on an
undiscounted basis. If the assessment indicates that the carrying amount of the
asset exceeds the undiscounted cash flows, an impairment has occurred. The
impairment is calculated as the total by which the carrying amount of the asset
exceeds its fair value. The fair value of long-lived assets and goodwill is
estimated based on quoted market prices, if available, or the expected total
value of the cash flows, on a discounted basis.
F-8
<PAGE> 22
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
Fair Value of Financial Instruments
The carrying values of cash, receivables, payables and accrued liabilities
approximate the fair values of these instruments because of their short-term
maturities.
Other Noncurrent Liabilities
Other liabilities is comprised of deposits from certain customers in
connection with pharmacy benefit contracts.
Revenue Recognition
Revenues from the dispensing of pharmaceuticals from the Company's mail
service pharmacy are recognized when each prescription is shipped. Revenues from
sales of prescription drugs by pharmacies in the Company's nationwide network
and claims processing fees are recognized when the claims are adjudicated. At
the point-of-sale, the pharmacy claims are adjudicated using the Company's
on-line claims processing system. When the Company has an independent obligation
to pay its network pharmacy providers, the Company includes payments from plan
sponsors for these benefits as revenues and payments to its pharmacy providers
as cost of revenues. If the Company is only administering plan sponsors' network
pharmacy contracts, the Company records the claims processing service fees as
revenues. Rebate revenues are recognized as they are earned in accordance with
contractual agreements. Certain of these revenues are based on estimates which
are subject to final settlement with the contract party. Revenues from certain
disease management and health benefit management products are reimbursed at
predetermined contractual rates based on the achievement of certain milestones.
Revenues are recognized as billed and based on the completion of the milestone
measurements.
Cost of Revenues
Cost of revenues includes product costs, pharmacy claims payments and other
direct costs associated with the sale and dispensing of prescriptions.
Federal Income Taxes
The Company files a consolidated federal income tax return which includes
the parent and all of its wholly owned subsidiaries.
F-9
<PAGE> 23
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
Net Income Per Share
In February 1997, the Financial Accounting Standards Board issued Statement
128, "Earnings Per Share" ("SFAS 128"). SFAS 128 is effective for financial
statements for both interim and annual periods ending after December 15, 1997.
SFAS 128 requires the calculation of "Basic" earnings per share which is
computed by dividing net income by the weighted average number of shares of
Common Stock outstanding during the period. In addition, SFAS 128 requires the
calculation of "Diluted" earnings per common share which is computed using the
weighted average number of shares of Common Stock and all other dilutive
securities. Other dilutive securities include stock options, stock warrants and
the Company's Series A and B preferred stock and are included in the "Diluted"
calculation only if the result is dilutive. A reconciliation of the numerators
and denominators of the basic and diluted per-share computations follows:
F-10
<PAGE> 24
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
<TABLE>
<CAPTION>
YEAR ENDED MARCH 31,
---------------------------------------
1996 1997 1998
----------- ----------- -----------
<S> <C> <C> <C>
BASIC
Numerator:
Net income $ 1,013,000 $ 3,226,000 $ 7,931,000
Preferred stock dividends 800,000 553,000 200,000
----------- ----------- -----------
$ 213,000 $ 2,673,000 $ 7,731,000
=========== =========== ===========
Denominator:
Weighted average common
stock outstanding 4,006,578 6,264,521 8,755,754
=========== =========== ===========
Net income per share $ 0.05 $ 0.43 $ 0.88
=========== =========== ===========
DILUTED
Numerator:
Net income $ 1,013,000 $ 3,226,000 $ 7,931,000
Preferred stock dividends 800,000 -- --
----------- ----------- -----------
$ 213,000 $ 3,226,000 $ 7,931,000
=========== =========== ===========
Denominator:
Weighted average common 4,006,578 6,264,521 8,755,754
stock outstanding
Other Dilutive Securities:
Series A preferred stock -- 1,250,000 --
Series B preferred stock -- 833,333 1,111,111
Options and warrants using the
treasury stock method 569,687 828,273 1,484,054
----------- ----------- -----------
Weighted average shares outstanding 4,576,265 9,176,127 11,350,919
=========== =========== ===========
Net income per share $ 0.05 $ 0.35 $ 0.70
=========== =========== ===========
</TABLE>
The conversion of the Series A preferred stock was anti-dilutive in 1996 and,
therefore, was not an other dilutive security.
F-11
<PAGE> 25
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
Reclassification
Certain prior year amounts have been reclassified to conform with current
year presentation.
Recent Accounting Pronouncements
The Company will adopt SFAS 130, "Reporting Comprehensive Income" effective
April 1, 1998. SFAS 130 established standards for reporting and display of
comprehensive income and its components in a full set of general-purpose
financial statements. Comprehensive income is defined as the total of net income
and all other non-owner changes in equity. The Company does not have any
non-owner changes in equity other than net income. Upon adoption, comprehensive
income and the cumulative other comprehensive income will be reported in a
consolidated statement of shareholders' equity.
The Company will adopt SFAS 131, "Disclosure about Segments of an
Enterprise and Related Information," effective April 1, 1998. This pronouncement
changes the requirements under which public businesses must report segment
information. The objective of the pronouncement is to provide information about
a company's different types of business activities and different economic
environments. SFAS 131 will require companies to select segments based on their
internal reporting system. Management is currently assessing the requirements of
this pronouncement and the effect it will have, if any, on the Company's
disclosure.
The Company will adopt SFAS 132, "Employers' Disclosures about Pensions and
Other Postretirement Benefits," as of April 1, 1998. This pronouncement revises
employers' disclosures about pension and other postretirement benefit plans. It
does not change the measurement or recognition of those plans, however, it does
require additional information on changes in the benefit obligations and fair
values of plan assets in order to facilitate financial analysis. Currently, the
Company does not have any pension or postretirement benefit plans, thus
management does not expect that the adoption of SFAS 132 will have a material
impact on the Company's disclosures.
3. BUSINESS COMBINATION
In February 1998, the Company completed a merger with IMR, a privately held
clinical trial and survey research firm based in Towson, Maryland. The Company
issued 876,078 shares and options to purchase 23,922 shares of its Common Stock
in exchange for all the outstanding shares and options of IMR.
F-12
<PAGE> 26
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
3. BUSINESS COMBINATION: (CONTINUED)
The merger constituted a tax-free reorganization and has been accounted for
as a pooling of interests under Accounting Principles Board Opinion No. 16 ("APB
16"). Accordingly, all prior period consolidated financial statements presented
have been restated to include the combined results of operations, financial
position and cash flows of IMR as though it had always been a part of the
Company.
The results of operations for the separate companies and the combined
amounts presented in the consolidated financial statements follow.
<TABLE>
<CAPTION>
Year Ended March 31,
1996 1997 1998
--------- --------- ---------
(000's)
<S> <C> <C> <C>
Revenues:
API $ 125,333 $ 251,562 $ 468,287
IMR 2,538 4,888 8,377
--------- --------- ---------
Combined $ 127,871 $ 256,450 $ 476,664
--------- --------- ---------
Net income:
API $ 1,037 $ 3,138 $ 7,165
IMR (24) 88 766
--------- --------- ---------
Combined $ 1,013 $ 3,226 $ 7,931
========= ========= =========
</TABLE>
In connection with the merger, the Company recorded in the fourth quarter a
charge to operating expenses of $689,000 ($427,000 after taxes, or $.04 per
common share on a dilutive basis) for professional fees and other merger-related
costs pertaining to the transaction.
4. PROPERTY AND EQUIPMENT:
Property and equipment consisted of the following:
<TABLE>
<CAPTION>
March 31,
--------------------------------
1997 1998
--------------- ---------------
<S> <C> <C>
Machinery and equipment................................................... $ 1,033,000 $ 3,521,000
Computer equipment and software........................................... 6,567,000 8,591,000
Furniture and equipment................................................... 1,149,000 1,381,000
Leasehold improvements.................................................... 792,000 1,017,000
Land and buildings........................................................ -- 1,558,000
--------------- ---------------
9,541,000 16,068,000
Less--Accumulated depreciation and amortization........................... (3,540,000) (5,574,000)
--------------- ---------------
$ 6,001,000 $ 10,494,000
=============== ===============
</TABLE>
F-13
<PAGE> 27
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
5. DEBT:
On July 1, 1996, IMR entered into a $1,000,000 line of credit agreement
with an officer and shareholder of IMR. As of March 31, 1997, $900,000 was
outstanding under the line of credit arrangement. Interest payments were due
quarterly and accrued at the prime rate. In addition, other officers and
shareholders of IMR made working capital loans to IMR during the periods
presented. Interest expense was $16,000, $66,000 and $67,000 in the years ended
March 31, 1996, 1997 and 1998, respectively. After the merger, the remaining
balance of the line of credit was paid and the credit arrangement was
terminated.
6. LEASES:
The Company leases office and dispensing facility space, equipment, and
automobiles under various operating leases. The Company was obligated to make
future minimum payments under noncancelable operating lease agreements as of
March 31, 1998, as follows:
<TABLE>
<CAPTION>
Years Ending
March 31,
- ------------
<S> <C>
1999................................................... $3,016,000
2000................................................... 2,575,000
2001................................................... 1,996,000
2002................................................... 1,479,000
2003................................................... 239,000
----------
Total minimum lease payments...................... $9,305,000
==========
</TABLE>
Total rent expense incurred in the years ended March 31, 1996, 1997 and
1998 was $1,185,000, $2,313,000 and $3,096,000, respectively.
7. COMMITMENTS AND CONTINGENCIES:
The Company has entered into long-term employment agreements with certain
management employees. These employment agreements provide for certain minimum
payments should the agreements be terminated.
F-14
<PAGE> 28
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
7. COMMITMENTS AND CONTINGENCIES: (CONTINUED)
The pharmacy industry is governed by extensive federal and state laws and
regulations. The regulatory requirements with which the Company must comply in
conducting its business vary from state to state. Management believes the
Company is in substantial compliance with, or is in the process of complying
with, all existing laws and regulations material to the operation of its
business. In management's opinion, any events of noncompliance would not have a
material adverse effect on the results of operations or financial condition of
the Company.
8. CONCENTRATION OF BUSINESS:
A significant portion of the Company's revenues result from contracts with
customers. These contracts normally have terms from one to five years with
renewal options.
One customer of the Company accounted for approximately 14% and 15% of the
Company's revenues for the years ended March 31, 1997 and 1998, respectively.
Another customer accounted for approximately 21% of the Company's revenues for
the year ended March 31, 1998. A third customer accounted for approximately 18%
of the Company's revenues for the year ended March 31, 1997, but revenues from
this customer did not exceed 10% of the Company's revenues for the year ended
March 31, 1998. A fourth customer accounted for approximately 18% of the
Company's revenues for the year ended March 31, 1996, but revenues from this
customer did not exceed 10% of the Company's revenues in either the year ended
March 31, 1997 or 1998. No other customer accounted for over 10% of the
Company's revenues in fiscal years 1996, 1997, or 1998.
9. STOCK TRANSACTIONS:
Series B Preferred Stock
On June 25, 1996, the Company issued a total of 4,444 shares of $.01 par
value, Series B convertible preferred stock ("Series B Preferred Stock") to a
customer at a price of $2,250 per share. Shares of the Series B Preferred Stock
may be converted by the holder into 250 fully-paid and non-assessable shares of
Common Stock. Holders of the Series B Preferred Stock are not entitled to vote
on any matter. Holders of the Series B Preferred Stock are entitled to receive,
out of funds legally available therefor, cumulative dividends, calculated
without compounding, equal to $45.00 per share per annum. Such cumulative
dividends accrue and accumulate from the date of issuance and are payable on
F-15
<PAGE> 29
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
9. STOCK TRANSACTIONS: (CONTINUED)
March 31 of each year. Furthermore, holders of the Series B Preferred Stock are
entitled to any dividends that the Board of Directors may declare to be payable
on shares of Common Stock as if the shares of Series B Preferred Stock had been
converted into shares of Common Stock. Upon the liquidation, dissolution or
winding up of the Company, holders of the Series B Preferred Stock have the
right, prior to any existing or future classes of capital stock, to receive
$10.0 million plus all accrued and unpaid dividends of Series B Preferred Stock
and to participate equally and ratably with holders of the Common Stock in the
net assets of the Company available for distribution to stockholders. The
Company, in its sole discretion, may redeem any or all of such holders' shares
at a price equal to the original price paid per share, plus accrued and unpaid
dividends. The Company has the right to convert the Series B Preferred Stock
into Common Stock at any time after the fifth anniversary of issuance. If the
Company forces such a conversion, holders of the Series B Preferred Stock will
be entitled to piggy-back registration rights in connection with future
registered offerings of shares of Common Stock.
On April 13, 1998, the Company was notified by the holders of the Series B
Preferred Stock that they were electing to convert all of the shares into Common
Stock. Subsequently, the shares were converted into 1,111,111 shares of Common
Stock.
Common Stock
On October 7, 1996, the Company amended and restated its Certificate of
Incorporation to, among other things, increase the number of authorized shares
of its $.01 par value common stock ("Common Stock") to 25,000,000 and the number
of shares of its preferred stock to 5,000,000, of which 5,000 shares are
designated as Series B Preferred Stock. On October 8, 1996, the Company effected
a 250-for-one stock split of the Company's Common Stock. Accordingly, all share
and per share amounts have been adjusted to reflect the stock split as though it
had occurred at the beginning of the initial period presented.
On October 8, 1996, the Company completed the Offering of its Common Stock.
On November 7, 1996, the Underwriters exercised the over-allotment option of the
Offering. Including the over-allotment option, the Company sold 2,397,067 shares
of its Common Stock at a price of $9.00 per share, prior to underwriting
discount and other offering expenses. In connection with the Offering, the
Company's redeemable Series Accumulative convertible preferred stock ("Series A
Preferred Stock") automatically converted into 2,500,000 shares of Common Stock.
F-16
<PAGE> 30
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
9. STOCK TRANSACTIONS: (CONTINUED)
Immediately prior to the consummation of the Offering, AHC was merged with
and into the Company (the "AHC Merger"). The AHC Merger was accounted for as a
reorganization of entities under common control in a manner similar to a pooling
of interests. Accordingly, the accounts of the predecessor were based on
historical cost, and its operations are included from the date of its formation.
Prior to the AHC Merger, AHC held 3,125,000 shares of the Company's Common
Stock. In connection with the AHC Merger, the AHC incentive stock option plan
was merged with the Company's Incentive Stock Option Plan, and holders of
options under the AHC incentive stock option plan received options to purchase
Common Stock under the Company's Incentive Stock Option Plan. In the AHC Merger,
the Company canceled the shares held by AHC and issued shares of Common Stock
directly to the AHC stockholders (the "AHC Stockholders") based upon their
fully-diluted proportionate ownership interests in AHC after giving
consideration to the new shares of AHC to be issued in repayment of debt as
indicated below. After the AHC Merger, there were 2,903,750 shares of Common
Stock outstanding and 229,750 additional options outstanding at exercise prices
ranging from $0.65 to $2.71 per share. Immediately prior to the AHC Merger, AHC
distributed the stock of certain subsidiaries of AHC, operating in businesses
unrelated to the Company, to the AHC Stockholders. Prior to such spin-off,
certain indebtedness owed by AHC to several of its stockholders (including
certain indebtedness of AHC payable to an affiliate of a preferred stockholder
of the Company which was assumed by an AHC stockholder) was exchanged for
additional shares of AHC common stock. The spin-off and exchange of indebtedness
did not impact the number of shares of the Company's Common Stock outstanding.
In connection with the IMR merger, the Company issued 876,078 shares of its
Common Stock in exchange for all the outstanding shares of IMR. Under the
provisions of APB 16, the shares are reflected as outstanding as though IMR had
always been a part of the Company. Therefore, the Company has 8,676,895 and
8,904,472 shares of Common Stock issued and outstanding at March 31, 1997 and
1998, respectively.
Warrants
During the year ended March 31, 1994, the Company issued warrants to
purchase 336,500 and 56,250 shares of its Common Stock at prices per share of
$4.00 and $6.00, respectively. During the year ended March 31, 1998, warrants to
purchase 158,573 and 56,250 shares at prices per share of $4.00 and $6.00,
respectively, were exercised.
F-17
<PAGE> 31
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
9. STOCK TRANSACTIONS: (CONTINUED)
During the year ended March 31, 1997, the Company agreed to issue to a
customer warrants to purchase 84,500 shares of its Common Stock at a price of
$8.10 per share. During the years ended March 31, 1996 and 1997, the Company
agreed to issue warrants to purchase 548,250 shares of its Common Stock at
prices ranging from $8.10 to $11.00 per share to two customers contingent upon
future expansion of member lives. As of March 31, 1998, no warrants have been
earned or issued.
In October 1995, the Financial Accounting Standards Board issued Statement
No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"). The Company
accounted for these warrant agreements under the provisions of FASB 123 and the
related Emerging Issues Task Force ("EITF") 96-3. These pronouncements require
that all stock issued to non-employees be accounted for based on the fair value
of the consideration received or the fair value of equity instruments issued. In
addition, they require that the fair value be measured on the date the parties
come to a "mutual understanding of the terms of the arrangement and agree to a
binding contract" (i.e. the grant date). If the number of equity instruments is
contingent upon the outcome of future events, the number of instruments that
should be accounted for when determining the fair value of the transaction
should be based on the best available estimate of the number of instruments
expected to be issued. In management's opinion, the fair value of the warrants
at the date of the agreements was not material.
Subsequent to November 20, 1997, the Company follows the guidance of EITF
96-18, under which the measurement date is the earlier of the performance
commitment date or completed performance date. The Company chose not to
retroactively apply EITF 96-18 to the eligible warrants, but chose to apply this
EITF prospectively to new arrangements and any modifications of existing
arrangements.
The Company has reserved shares of Common Stock at March 31, 1998, for the
following:
<TABLE>
<CAPTION>
<S> <C>
Conversion of Series B Preferred Stock..................................... 1,111,111
Exercise of stock options.................................................. 2,793,948
Exercise of warrants....................................................... 810,677
---------
4,715,736
</TABLE>
F-18
<PAGE> 32
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
10. STOCK OPTION PLAN:
At March 31, 1998 the Company has three stock-based compensation plans:
Incentive Stock Option Plan, Amended and Restated Incentive Stock Option Plan
and the 1997 Nonstatutory Stock Option Plan (the "Plans"). The Plans provide for
the granting of qualified stock options and incentive options to officers,
directors, advisors and employees of the Company. The options must be granted
with exercise prices which equal or exceed the market value of the Common Stock
at the date of grant. As of March 31, 1998, the number of shares of Common Stock
issuable under the Plans may not exceed 2,837,750 shares. The Plans are
administered by a compensation committee appointed by the Board of Directors of
the Company.
The stock options generally vest over 5-year periods. In the event of the
sale or merger with an outside corporation gaining 50% or greater ownership,
options granted to certain employees become 100% vested. The options are
exercisable for a period not to exceed 10 years from the date of grant. As of
March 31, 1998, 879,382 options were vested at exercise prices of $.65 to $19.75
per share.
SFAS 123 establishes a fair value-based method of accounting for
stock-based compensation. The Company has elected to adopt SFAS 123 through
disclosure with respect to employee stock-based compensation. The following
table summarizes the Company's stock option activity.
<TABLE>
<CAPTION>
1996 1997 1998
------------------------------------------------------------------------------
Shares Wtd. Avg. Shares Wtd. Avg. Shares Wtd. Avg.
Ex. Price Ex. Price Ex. Price
---------- ---------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning of year 783,500 $ 7.80 810,500 $ 5.15 1,457,750 $ 6.02
Granted 195,500 12.82 445,000 10.34 614,375 21.25
Transferred from AHC -- -- 229,750 1.12 -- --
Transferred from IMR -- -- -- -- 23,922 1.18
Exercised (5,500) 3.20 (3,000) 3.20 (43,052) 5.26
Canceled (163,000) 27.12 (24,500) 10.75 (29,250) 9.78
---------- ---------- ---------- ---------- ---------- ----------
Outstanding at end of year 810,500 5.15 1,457,750 6.02 2,023,745 10.54
========== ========== ========== ========== ========== ==========
Exercisable at end of year 276,500 5.84 632,850 2.95 879,382 4.40
Price range $3.20 to $11.00 $.65 to $19.75 $.65 to $33.13
Weighted average fair value
of options granted $3.88 $3.31 $ 7.94
</TABLE>
F-19
<PAGE> 33
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
10. STOCK OPTION PLAN: (CONTINUED)
The following table reflects the weighted average exercise price and
weighted average contractual life of various exercise price ranges of the
2,023,745 options outstanding as of March 31, 1998.
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
---------------------------------------- ---------------------------
Weighted Wtd. Avg. Weighted
Avg. Exercise Contractual Avg. Exercise
Exercise Price Range Shares Price Life (yrs.) Shares Price
- -------------------- -------- ------------- ----------- --------- -------------
<S> <C> <C> <C> <C> <C>
$ .65 to $ 2.71 248,670 $ 1.14 3.7 224,748 $ 1.13
$ 3.20 to $ 4.80 580,200 $ 3.26 5.4 460,500 $ 3.25
$ 9.00 to $ 12.50 877,875 $ 11.12 8.6 192,467 $ 10.84
$ 16.63 to $ 20.75 64,000 $ 19.55 9.3 1,667 19.75
$ 29.13 to $ 33.13 253,000 $ 32.21 9.9 --- ---
</TABLE>
The fair value of each option grant is estimated on the date of the grant
using the Black-Scholes option pricing model with the following weighted average
ranges of assumptions for the years ended March 31, 1996, 1997 and 1998,
respectively: risk-free interest rates of 4.8% to 6.5%; expected lives of three
to five years; expected volatility of 30% to 50%. The Company continues to
account for stock based compensation under APB 25, "Accounting for Stock Issued
to Employees", as allowed by SFAS 123. Had compensation cost for these plans
been determined consistent with SFAS 123, the Company's net income and net
income per share would have been reduced to the following pro forma amounts:
<TABLE>
<CAPTION>
1996 1997 1998
------------- ------------- -------------
<S> <C> <C> <C>
Net income:
As reported $ 1,013,000 $ 3,226,000 $ 7,931,000
Pro forma $ 1,003,000 $ 3,065,000 $ 7,382,000
Basic net income per share:
As reported $ 0.05 $ 0.43 $ 0.88
Pro forma $ 0.05 $ 0.40 $ 0.82
Diluted net income per share:
As reported $ 0.05 $ 0.35 $ 0.70
Pro forma $ 0.04 $ 0.33 $ 0.65
</TABLE>
Because SFAS 123 method of accounting has not been applied to options granted
prior to April 1, 1995, the resulting pro forma compensation cost may not be
representative of that to be expected in future years.
F-20
<PAGE> 34
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
11. RELATED PARTY TRANSACTIONS:
In fiscal 1998, the Company entered into an agreement with Advance Capital
Markets ("ACM") pursuant to which ACM agreed to act as financial advisor for the
IMR transaction. In exchange for these professional services, the Company paid
ACM a fee of $150,000, which is equivalent to or less than similar fees incurred
in arm's-length transactions. The Managing Director of ACM is also a Director of
the Company.
12. RETIREMENT PLAN BENEFITS:
The Company sponsors a retirement plan for all eligible employees, as
defined in the plan document. The plan is qualified under Section 401(k) of the
Internal Revenue Code. The Company is required to contribute at least 50% of the
first 6% of salary deferral contributed by each participant. The Company's
contributions to the plan amounted to approximately $102,000, $129,000 and
$177,000 for the years ended March 31, 1996, 1997 and 1998, respectively.
13. INCOME TAXES:
The provision for income taxes for the year ended March 31, 1998 differed
from the amounts computed by applying the U.S. federal tax rate of 34 percent to
pretax earnings as a result of the following:
<TABLE>
<CAPTION>
1996 1997 1998
----------- ----------- -----------
<S> <C> <C> <C>
Tax at U.S. federal $ 344,000 $ 1,629,000 $ 4,349,000
income tax rate
State taxes -- -- 457,000
Benefit of operating (382,000) (89,000) --
loss carryforwards
Other, net 38,000 24,000 55,000
----------- ----------- -----------
Provision for income taxes $ -- $ 1,564,000 $ 4,861,000
=========== =========== ===========
</TABLE>
Of the $4,861,000 provision for income taxes in 1998, $441,000 represents
deferred income taxes and $4,420,000 represents the current portion.
F-21
<PAGE> 35
ADVANCE PARADIGM, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
Deferred income taxes reflect the tax consequences on future years of
temporary differences between the tax bases of assets and liabilities and their
financial reporting bases and the potential benefits of certain tax
carryforwards. The significant deferred tax assets and liabilities and the
changes in those assets and liabilities are as follows:
<TABLE>
<CAPTION>
March 31, March 31,
1997 Changes 1998
------------- ------------- -------------
<S> <C> <C> <C>
Gross deferred tax asset:
Other accruals.................................. $ 50,000 $ 7,000 $ 57,000
Other........................................... 48,000 2,000 50,000
------------- ------------- -------------
98,000 9,000 107,000
------------- ------------- -------------
Gross deferred tax liability:
Amortization of goodwill........................ (654,000) (196,000) (850,000)
Depreciation.................................... (288,000) (254,000) (542,000)
------------- ------------- -------------
(942,000) (450,000) (1,392,000)
------------- ------------- -------------
Net deferred tax liability...................... $ (844,000) $ (441,000) $ (1,285,000)
============= ============= =============
</TABLE>
F-22
<PAGE> 36
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14 -- OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table sets forth the estimated expenses, other than
underwriting discounts and commissions, payable by the Registrant in connection
with the issuance and distribution of the securities being registered hereby.
<TABLE>
<CAPTION>
<S> <C>
Securities and Exchange Commission Filing Fee ...................... $ 9,275.00
Printing Costs ..................................................... $ 2,000.00
Legal and Accounting Fees and Expenses.............................. $ 15,000.00
Total...................................................... $ 26,275.00
</TABLE>
ITEM 15 -- INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Company, a Delaware corporation, is empowered by Section 145 of the
Delaware General Corporation Law (the "Delaware Act"), subject to the procedures
and limitations stated therein, to indemnify certain parties. Section 145 of the
Delaware Act provides in part that a corporation shall have the power to
indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding (other than
an action by or in the right of the corporation) by reason of the fact that such
person is or was a director, officer, employee or agent of the corporation or is
or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation or other enterprise, against expenses
(including attorneys' fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or
proceeding if he acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the corporation, and with respect
to any criminal action or proceeding, had no reasonable cause to believe his
conduct was unlawful. Similar indemnity is authorized for such persons against
expenses (including attorneys' fees) actually and reasonably incurred in defense
or settlement of any threatened, pending or completed action or suit by or in
the right of the corporation, if such person acted in good faith and in a manner
he reasonably believed to be in or not opposed to the best interests of the
corporation, and provided further that (unless a court of competent jurisdiction
otherwise provides) such person shall not have been adjudged liable to the
corporation. Any such indemnification may be made only as authorized in each
specific case upon a determination by the stockholders or disinterested
directors that indemnification is proper because the indemnitee has met the
applicable standard of conduct. Where an officer or a director is successful on
the merits or otherwise in the defense of any action referred to above, the
corporation must indemnify him against the expenses which such officer or
director actually or reasonably incurred. Section 145 provides further that
indemnification pursuant to its provisions is not exclusive of other rights of
indemnification to which a person may be entitled under any bylaw, agreement,
vote of stockholders or disinterested directors or otherwise.
Article 10 of the Company's Certificate of Incorporation, as amended
(the "Certificate"), provides that the Company shall indemnify any and all
persons whom it has the power to indemnify under Section 145 of the Delaware Act
to the fullest extent permitted under such section, and such indemnity shall
continue as to a person who has ceased to be a director, officer, employee or
agent and shall inure to the benefit of the heirs, executors and administrators
of such a person.
Article 9 of the Company's Certificate eliminates the personal
liability of the Company's directors to the fullest extent permitted under
Section 102(b)7 of the Delaware Act, as amended. Such section permits a
company's certificate of incorporation to eliminate or limit personal liability
of a director to the corporation or its stockholders for monetary damages for
breach of fiduciary duty as a director, provided that such provision shall not
eliminate or limit the liability of a director: (i) for any breach of the
director's duty of loyalty to the corporation or its stockholders; (ii) for acts
or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law; (iii) under section 174 of the Delaware Act (which
addresses director liability for unlawful payment of a dividend or unlawful
stock purchase or redemption) or (iv) for any transaction from which the
director derived an improper personal benefit.
As set forth below, Article 8 of the bylaws of the Company (the
"Bylaws") provides for indemnification of directors, officers, employees and
agents, and Section 8.8 of the Bylaws provides for the authority to purchase
insurance with respect to indemnification of directors, officers, employees and
agents.
II-1
<PAGE> 37
Article 8 of the Bylaws provides that the Company shall indemnify any
person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action by or in the
right of the Company) by reason of the fact that he is or was a director,
officer, employee or agent of the Company, or is or was serving at the request
of the Company as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses
(including attorneys' fees), judgments, fines, and amounts paid in settlement
actually and reasonably incurred by him in connection with such action, suit or
proceeding if he acted in good faith and in a manner he reasonably believed to
be in or not opposed to the best interests of the Company, and, with respect to
any criminal action or proceeding, had no reasonable cause to believe his
conduct was unlawful, to the fullest extent permitted by Delaware law.
The right to indemnification under Article 8 of the Bylaws is a
contract right which includes, with respect to directors, officers, employees
and agents, the right to be paid by the Company the expenses incurred in
defending a civil or criminal action, suit or proceeding in advance of its
disposition; provided, however, that, if the General Corporation Law of the
State of Delaware requires, the payment of such expenses incurred by a director
or officer in advance of the final disposition of a proceeding shall be made
only upon delivery to the Company of an undertaking, by or on behalf of such
director or officer, to repay all amounts so advanced if it shall ultimately be
determined that such director or officer is not entitled to be indemnified under
Article 8 or otherwise.
The Company maintains directors' and officers' liability insurance in
accordance with Delaware law.
II-2
<PAGE> 38
ITEM 16 -- EXHIBITS
The following Exhibits are filed as part of this Registration
Statement:
EXHIBIT DESCRIPTION
NUMBER
3.1 --Amended and Restated Certificate of Incorporation of the Company
(previously filed in connection with the Company's Registration
Statement on Form S-1, Commission File No. 333-06931, and
incorporated herein by reference)
3.2 --Amended and Restated Bylaws of the Company (previously filed in
connection with the Company's Registration Statement on Form S-1,
Commission File No. 333-06931, and incorporated herein by reference)
4.1 --Form of Stock Certificate of Common Stock of the Company (previously
filed in connection with the Company's Annual Report on Form 10-K for
the fiscal year ended March 31, 1997 and incorporated herein by
reference)
5.1 --Opinion of Akin, Gump, Strauss, Hauer & Feld, L.L.P.
23.1 --Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P. (included in
Exhibit 5.1)
23.2 --Consent of Arthur Andersen LLP
24.1 --Power of Attorney (included in the signature page of this
Registration Statement)
ITEM 17 -- UNDERTAKINGS
(a) The undersigned Company hereby undertakes:
(1) To file, during any period in which offers or sales
are being made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section
10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or
events arising after the effective date of this Registration Statement (or the
most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in this
Registration Statement. Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of securities offered
would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule 424 (b) if, in the
aggregate, the changes in volume and price represent no more than a 20% change
in the maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective Registration Statement;
(iii) to include any material information with
respect to the plan of distribution not previously disclosed in this
Registration Statement or any material change to such information in the
Registration Statement;
(2) that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered herein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof; and
II-3
<PAGE> 39
(3) to remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the Offering.
(b) The undersigned Company hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the Company's
annual report pursuant to Section 13 (a) or section 15 (d) of the Exchange Act
that is incorporated by reference in this Registration Statement shall be deemed
to be a new registration statement relating to the securities offered herein,
and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof;
(c) Insofar as indemnification for liabilities arising under the
Securities act may be permitted to directors, officers and controlling persons
of the Company pursuant to the foregoing provisions, or otherwise, the Company
has been advised that in the opinion of the Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Company of expenses incurred or paid
by a director, officer or controlling person of the Company in the successful
defense of any action, suit, or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being
registered, the Company will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
II-4
<PAGE> 40
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Company certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Irving, State of Texas, on June 2, 1998.
ADVANCE PARADIGM, INC.
By: /s/ David D. Halbert
---------------------------------------
David D. Halbert
Chairman of the Board, President
and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears
below constitutes and appoints David D. Halbert and Danny Phillips, and each of
them, with the power to act without the other, his true and lawful
attorneys-in-fact and agents, with full power of substitution and
resubstitution, for him in his name, place and stead, in any and all capacities,
to sign on his behalf individually and in each capacity stated below any or all
amendments or post-effective amendments to this Registration Statement, and to
file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or either of them, or their substitutes, may
lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed by the following persons in the
capacities indicated on June 2, 1998.
<TABLE>
<CAPTION>
SIGNATURE TITLE
- --------- ------
<S> <C>
/s/ David D. Halbert Chairman of the Board, President and Chief Executive
- --------------------------------------------- Officer
David D. Halbert
/s/ Jon S. Halbert Chief Operating Officer, Executive Vice President and
- --------------------------------------------- Director
Jon S. Halbert
/s/ T. Danny Phillips Chief Financial Officer, Senior Vice President,
- --------------------------------------------- Secretary and Treasurer (Principal Financial and
T. Danny Phillips Accounting Officer)
/s/ Peter M. Castleman Director
- ---------------------------------------------
Peter M. Castleman
/s/ Rogers K. Coleman Director
- ---------------------------------------------
Rogers K. Coleman
/s/ Stephen L. Green Director
- ---------------------------------------------
Stephen L. Green
/s/ Jeffrey R. Jay Director
- ---------------------------------------------
Jeffrey R. Jay
/s/ Kenneth J. Linde Director
- ---------------------------------------------
Kenneth J. Linde
/s/ Michael D. Ware Director
- ---------------------------------------------
Michael D. Ware
</TABLE>
II-5
<PAGE> 41
EXHIBIT INDEX
<TABLE>
<S> <C>
3.1 --Amended and Restated Certificate of Incorporation of the Company
(previously filed in connection with the Company's Registration
Statement on Form S-1, Commission File No. 333-06931, and
incorporated herein by reference)
3.2 --Amended and Restated Bylaws of the Company (previously filed in
connection with the Company's Registration Statement on Form S-1,
Commission File No. 333-06931, and incorporated herein by reference)
4.1 --Form of Stock Certificate of Common Stock of the Company (previously
filed in connection with the Company's Annual Report on Form 10-K for
the fiscal year ended March 31, 1997 and incorporated herein by
reference)
5.1 --Opinion of Akin, Gump, Strauss, Hauer & Feld, L.L.P.
23.1 --Consent of Akin, Gump, Strauss, Hauer & Feld, L.L.P. (included in
Exhibit 5.1)
23.2 --Consent of Arthur Andersen LLP
24.1 --Power of Attorney (included in the signature page of this
Registration Statement)
</TABLE>
<PAGE> 1
EXHIBIT 5.1
[AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P. LETTERHEAD]
May 27, 1998
Advance Paradigm, Inc.
545 East John Carpenter Freeway
Suite 1570
Irving, Texas 75062
Ladies and Gentlemen:
We have acted as counsel to Advance Paradigm, Inc., a Delaware
corporation (the "Company"), in connection with the proposed registration of
876,078 shares of the Company's common stock, $.01 par value (the "Common
Stock"), as described in a registration statement on Form S-3 (the "Registration
Statement"), which Registration Statement is to be filed with the Securities and
Exchange Commission.
We have, as counsel, examined such corporate records, certificates and
other documents and reviewed such questions of law as we have deemed necessary,
relevant or appropriate to enable us to render the opinions listed below. In
rendering such opinions, we have assumed the genuineness of all signatures and
the authenticity of all documents examined by us. As to various questions of
fact material to such opinions, we have relied upon representations of the
Company.
Based upon such examination and representations, we advise you that, in
our opinion:
A. The shares of Common Stock which are to be registered pursuant to
the Registration Statement have been duly and validly authorized by the Company.
B. The shares of Common Stock which are to be registered pursuant to
the Registration Statement have been validly issued, are fully paid and are
non-assessable.
The foregoing opinion is limited to the corporate laws of the State of
Delaware, and we express no opinion as to the effect on the matters covered by
this letter of any other law.
<PAGE> 2
We consent to the reference to this firm in the Registration Statement
and to the filing of this opinion as Exhibit 5.1 to the Registration Statement.
This opinion is rendered solely to you in connection with the above
matter. This opinion may not be relied upon by you for any other purpose or
relied upon by or furnished to any other person without our prior written
consent.
Sincerely,
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
<PAGE> 1
EXHIBIT 23.2
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the use of our report
dated May 15, 1998, and to all references to our firm included in or made a
part of this registration statement.
By: /s/ Arthur Andersen LLP
-------------------------------
Dallas, Texas
June 2, 1998
